PharmaPhorum has an excellent analysis on launch evolution across pharmerging markets, such as China, Brazil, Russia, and so forth. A few items of note: 1. The author projects that by…
Today we learn that Lilly is acquiring Avid Radiopharmaceuticals: Lilly will acquire all outstanding shares of Avid for an upfront payment of $300 million, subject to adjustment based on existing cash on…
Fascinating turn of events on Friday, when the DOJ: said on Friday that human and other genes should not be eligible for patents because they are part of nature This…
The October, 2010 issue of Life Science Leader has an interesting article entitled Orphan Drugs: Big Pharma's Next Act? The premise is that Big Pharma is turning towards orphan drug…
A former business development colleague of mine used to refer to some prospects as having "champagne tastes with beer wallets." His meaning was clear. It's one thing to want champagne,…
Today we learned that Lilly will close their Singapore R&D facility. This facility was focused on drug discovery in cancer and diabetes. I leave it to the powers that be…
It is regrettable that the FDA issued a complete response letter to Jazz Pharmaceuticals for JZP-6. If there is a disease that can use some innovation, it's fibromyalgia. The CRL…
Physicians typically don't interact with their patients via email. This is understandable and quite interesting, as physicians tend to be quite computer savvy. A recent report explains the reasons why this is the case.
Drug delivery is not dead! In fact, drug delivery can ba a valuable tool for developing and commercializing drugs faster and at lower cost versus NCEs.
Late last month, Johnson and Johnson (J&J) announced the results of Phase III clinical trials comparing tapentadol extended release compared to oxycodone controlled release and placebo. In this study, J&J…